 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ENALAPRIL MALEATE increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ENALAPRIL MALEATE increase the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ENALAPRIL MALEATE increase the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ENALAPRIL MALEATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ENALAPRIL MALEATE: drug_interactions: Other Cardiovascular Agents Enalapril maleate has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking [0m
[31magents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions. Agents Increasing Serum Potassium Enalapril attenuates potassium loss caused by thiazide-type[0m
[31mdiuretics. Potassium-sparing diuretics [0m[1;31m([0m[31me.g., spironolactone, triamterene, or amiloride[0m[1;31m)[0m[31m, potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum [0m
[31mpotassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. [0m
[31mPotassium-sparing agents should generally not be used in patients with heart failure receiving enalapril maleate. ENALAPRIL MALEATE: drug_interactions: Lithium Lithium toxicity has been reported in [0m
[31mpatients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving concomitant [0m
[31menalapril maleate and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly [0m
[31mwith lithium. Gold Nitritoid reactions [0m[1;31m([0m[31msymptoms include facial flushing, nausea, vomiting and hypotension[0m[1;31m)[0m[31m have been reported rarely in patients on therapy with injectable gold [0m[1;31m([0m[31msodium [0m
[31maurothiomalate[0m[1;31m)[0m[31m and concomitant ACE inhibitor therapy including enalapril maleate. mTOR [0m[1;31m([0m[31mMammalian Target of Rapamycin[0m[1;31m)[0m[31m Inhibitors Patients receiving coadministration of ACE inhibitor and mTOR [0m
[31minhibitor [0m[1;31m([0m[31me.g. ENALAPRIL MALEATE: drug_interactions: temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m therapy may be at increased risk for angioedema [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: adverse_reactions: Cardiovascular Cardiac arrest; myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients [0m[1;31m([0m[31msee [0m
[31mWARNINGS, Hypotension [0m[1;31m)[0m[31m; pulmonary embolism and infarction; pulmonary edema; rhythm disturbances including atrial tachycardia and bradycardia; atrial fibrillation; palpitation, Raynaud's phenomenon. [0m
[31mDigestive Ileus, pancreatitis, hepatic failure, hepatitis [0m[1;31m([0m[31mhepatocellular [0m[31m or cholestatic jaundice[0m[1;31m)[0m[31m [0m[1;31m([0m[31msee WARNINGS, Hepatic Failure [0m[1;31m)[0m[31m, melena, anorexia, dyspepsia, constipation, glossitis, stomatitis, [0m
[31mdry mouth. Hematologic Rare cases of neutropenia, thrombocytopenia and bone marrow depression. Musculoskeletal Muscle cramps. ENALAPRIL MALEATE: adverse_reactions: Nervous/Psychiatric Depression, [0m
[31mconfusion, ataxia, somnolence, insomnia, nervousness, peripheral neuropathy [0m[1;31m([0m[31me.g., paresthesia, dysesthesia[0m[1;31m)[0m[31m, dream abnormality. Respiratory Bronchospasm, rhinorrhea, sore throat and hoarseness, [0m
[31masthma, upper respiratory infection, pulmonary infiltrates, eosinophilic pneumonitis. Skin Exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pemphigus, herpes zoster, [0m
[31merythema multiforme, urticaria, pruritus, alopecia, flushing, diaphoresis, photosensitivity. Special Senses Blurred vision, taste alteration, anosmia, tinnitus, conjunctivitis, dry eyes, tearing. [0m
[31mENALAPRIL MALEATE: adverse_reactions: Urogenital Renal failure, oliguria, renal dysfunction [0m[1;31m([0m[31msee PRECAUTIONS and DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m, flank pain, gynecomastia, impotence. Miscellaneous A [0m
[31msymptom complex has been reported which may include some or all of the following: a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia/myositis, fever, serositis, [0m
[31mvasculitis, leukocytosis, eosinophilia, photosensitivity, rash and other dermatologic manifestations. Angioedema Angioedema has been reported in patients receiving enalapril maleate, with an incidence[0m
[31mhigher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. ENALAPRIL MALEATE: adverse_reactions: If angioedema of the face, extremities, lips, tongue, glottis[0m
[31mand/or larynx occurs, treatment with enalapril maleate should be discontinued and appropriate therapy instituted immediately [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m. Hypotension In the hypertensive [0m
[31mpatients, hypotension occurred in [0m[1;31m0.9[0m[31m percent and syncope occurred in [0m[1;31m0.5[0m[31m percent of patients following the initial dose or during extended therapy. Hypotension or syncope was a cause for [0m
[31mdiscontinuation of therapy in [0m[1;31m0.1[0m[31m percent of hypertensive patients. In heart failure patients, hypotension occurred in [0m[1;31m6.7[0m[31m percent and syncope occurred in [0m[1;31m2.2[0m[31m percent of patients. Hypotension or [0m
[31msyncope was a cause for discontinuation of therapy in [0m[1;31m1.9[0m[31m percent of patients with heart failure [0m[1;31m([0m[31msee WARNINGS, Hypotension [0m[1;31m)[0m[31m. Cough See PRECAUTIONS, Cough . ENALAPRIL MALEATE: adverse_reactions: [0m
[31mPediatric Patients The adverse experience profile for pediatric patients appears to be similar to that seen in adult patients. Clinical Laboratory Test Findings Serum Electrolytes Hyperkalemia [0m[1;31m([0m[31msee [0m
[31mPRECAUTIONS, Hyperkalemia [0m[1;31m)[0m[31m, hyponatremia. Creatinine, Blood Urea Nitrogen In controlled clinical trials minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of[0m
[31mtherapy, were observed in about [0m[1;31m0.2[0m[31m percent of patients with essential hypertension treated with enalapril maleate alone. Increases are more likely to occur in patients receiving concomitant diuretics[0m
[31mor in patients with renal artery stenosis [0m[1;31m([0m[31msee PRECAUTIONS, Impaired Renal Function [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: adverse_reactions: In patients with heart failure who were also receiving diuretics with or [0m
[31mwithout digitalis, increases in blood urea nitrogen or serum creatinine, usually reversible upon discontinuation of enalapril maleate and/or other concomitant diuretic therapy, were observed in about [0m
[1;31m11[0m[31m percent of patients. Increases in blood urea nitrogen or creatinine were a cause for discontinuation in [0m[1;31m1.2[0m[31m percent of patients. Hematology Small decreases in hemoglobin and hematocrit [0m[1;31m([0m[31mmean [0m
[31mdecreases of approximately [0m[1;31m0.3[0m[31m g percent and [0m[1;31m1[0m[31m vol percent, respectively[0m[1;31m)[0m[31m occur frequently in either hypertension or congestive heart failure patients treated with enalapril maleate but are rarely of [0m
[31mclinical importance unless another cause of anemia coexists. In clinical trials, less than [0m[1;31m0.1[0m[31m percent of patients discontinued therapy due to anemia.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: contraindications: CONTRAINDICATIONS Enalapril maleate tablets, USP are contraindicated in patients who are hypersensitive to this product and in patients with a history of[0m
[31mangioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. Do not coadminister aliskiren with enalapril maleate [0m
[31min patients with diabetes [0m[1;31m([0m[31msee PRECAUTIONS, Drug Interactions [0m[1;31m)[0m[31m. Enalapril maleate tablets, USP are contraindicated in combination with a neprilysin inhibitor [0m[1;31m([0m[31me.g., sacubitril[0m[1;31m)[0m[31m. Do not administer [0m
[31menalapril maleate tablets USP within [0m[1;31m36[0m[31m hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [0m[1;31m([0m[31msee WARNINGS , Head and Neck Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: indications_and_usage: INDICATIONS AND USAGE Hypertension Enalapril maleate tablets, USP are indicated for the treatment of hypertension. Enalapril maleate tablets, USP are[0m
[31meffective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately [0m
[31madditive. Heart Failure Enalapril maleate tablets, USP are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients [0m
[31menalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of [0m
[31msurvival trials[0m[1;31m)[0m[31m. ENALAPRIL MALEATE: indications_and_usage: Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction [0m[1;31m([0m[31mejection fraction [0m
[31mâ‰¤[0m[1;31m35[0m[31m percent[0m[1;31m)[0m[31m, enalapril maleate tablets, USP decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY, Heart[0m
[31mFailure, Mortality Trials for details and limitations of survival trials[0m[1;31m)[0m[31m. In using enalapril maleate, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, [0m
[31mcaptopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not [0m
[31mhave a similar risk [0m[1;31m([0m[31msee WARNINGS , Neutropenia/Agranulocytosis [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: indications_and_usage: In considering use of enalapril maleate, it should be noted that in controlled clinical [0m
[31mtrials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been [0m
[31mreported to have a higher incidence of angioedema compared to non-blacks [0m[1;31m([0m[31msee WARNINGS, Head and Neck Angioedema [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: information_for_patients: Information for Patients Angioedema Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin-converting [0m
[31menzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema [0m[1;31m([0m[31mswelling of face, extremities, eyes, lips, tongue, [0m
[31mdifficulty in swallowing or breathing[0m[1;31m)[0m[31m and to take no more drug until they have consulted with the prescribing physician. Hypotension Patients should be cautioned to report lightheadedness, especially[0m
[31mduring the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician. All patients should be [0m
[31mcautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. ENALAPRIL MALEATE: information_for_patients: Other causes of[0m
[31mvolume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician. Hyperkalemia Patients should be told not to use salt [0m
[31msubstitutes containing potassium without consulting their physician. Neutropenia Patients should be told to report promptly any indication of infection [0m[1;31m([0m[31me.g., sore throat, fever[0m[1;31m)[0m[31m which may be a sign [0m
[31mof neutropenia. Pregnancy Female patients of childbearing age should be told about the consequences of exposure to enalapril maleate during pregnancy. Discuss treatment options with women planning to [0m
[31mbecome pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible. NOTE: As with many other drugs, certain advice to patients being treated with enalapril is [0m
[31mwarranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m


[31mCONTENT: ENALAPRIL MALEATE: warnings: WARNINGS Anaphylactoid and Possibly Related Reactions Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and [0m
[31mpolypeptides, including endogenous bradykinin, patients receiving ACE inhibitors [0m[1;31m([0m[31mincluding enalapril maleate[0m[1;31m)[0m[31m may be subject to a variety of adverse reactions, some of them serious. Head and Neck [0m
[31mAngioedema Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including enalapril maleate. [0m
[31mThis may occur at any time during treatment. In such cases enalapril maleate should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained [0m
[31mresolution of signs and symptoms has occurred. ENALAPRIL MALEATE: warnings: In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, [0m
[31malthough antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause [0m
[31mairway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution [0m[1;31m1:1000[0m[31m [0m[1;31m([0m[1;31m0.3[0m[31m mL to [0m[1;31m0.5[0m[31m mL[0m[1;31m)[0m[31m and/or measures necessary to ensure a patent airway, should be promptly provided [0m[1;31m([0m[31msee ADVERSE[0m
[31mREACTIONS [0m[1;31m)[0m[31m. Patients receiving coadministration of ACE inhibitor and mTOR [0m[1;31m([0m[31mmammalian target of rapamycin[0m[1;31m)[0m[31m inhibitor [0m[1;31m([0m[31me.g., temsirolimus, sirolimus, everolimus[0m[1;31m)[0m[31m therapy or a neprilysin inhibitor may [0m
[31mbe at increased risk for angioedema [0m[1;31m([0m[31msee PRECAUTIONS [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: warnings: Intestinal Angioedema Intestinal angioedema has been reported in patients treated with ACE inhibitors. These [0m
[31mpatients presented with abdominal pain [0m[1;31m([0m[31mwith or without nausea or vomiting[0m[1;31m)[0m[31m; in some cases there was no prior history of facial angioedema and C1 esterase levels were normal. The angioedema was [0m
[31mdiagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential [0m
[31mdiagnosis of patients on ACE inhibitors presenting with abdominal pain. Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving [0m
[31man ACE inhibitor [0m[1;31m([0m[31msee INDICATIONS AND USAGE and CONTRAINDICATIONS [0m[1;31m)[0m[31m. Anaphylactoid Reactions During Desensitization Two patients undergoing desensitizing treatment with hymenoptera venom while [0m
[31mreceiving ACE inhibitors sustained life-threatening anaphylactoid reactions. ENALAPRIL MALEATE: warnings: In the same patients, these reactions were avoided when ACE inhibitors were temporarily [0m
[31mwithheld, but they reappeared upon inadvertent rechallenge. Anaphylactoid Reactions During Membrane Exposure Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes [0m
[31mand treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. Hypotension [0m
[31mExcessive hypotension is rare in uncomplicated hypertensive patients treated with enalapril maleate alone. Patients with heart failure given enalapril maleate commonly have some reduction in blood [0m
[31mpressure, especially with the first dose, but discontinuation of therapy for continuing symptomatic hypotension usually is not necessary when dosing instructions are followed; caution should be [0m
[31mobserved when initiating therapy [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. ENALAPRIL MALEATE: warnings: Patients at risk for excessive hypotension, sometimes associated with oliguria and/or progressive [0m
[31mazotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high-dose diuretic therapy, recent intensive [0m
[31mdiuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. It may be advisable to eliminate the diuretic [0m[1;31m([0m[31mexcept in patients with heart failure[0m[1;31m)[0m[31m, [0m
[31mreduce the diuretic dose or increase salt intake cautiously before initiating therapy with enalapril maleate in patients at risk for excessive hypotension who are able to tolerate such adjustments [0m
[1;31m([0m[31msee PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS [0m[1;31m)[0m[31m.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mNALAPRIL MALEATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Yes, ENALAPRIL MALEATE does increase the risk of angioedema. Angioedema has been reported in patients receiving enalapril maleate, with a higher incidence in black patients compared to [0m
[32mnon-black patients. Angioedema associated with laryngeal edema can be fatal. If angioedema occurs, treatment with enalapril maleate should be discontinued and appropriate therapy instituted [0m
[32mimmediately.[0m

[32mSOURCE: ENALAPRIL MALEATE label[0m
[32mEXTRACT_START_END: Angioedema Angioedema has been reported [0m[32m...[0m[32m with laryngeal edema may be fatal.[0m
*[1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Yes, ENALAPRIL MALEATE does increase the risk of angioedema. [0m
[34mAngioedema has been reported in patients receiving enalapril maleate, with a higher incidence in black patients compared to non-black patients. Angioedema associated with laryngeal edema can be fatal.[0m
[34mIf angioedema occurs, treatment with enalapril maleate should be discontinued and appropriate therapy instituted immediately.[0m

[34mSOURCE: ENALAPRIL MALEATE label[0m
[34mEXTRACT_START_END: Angioedema Angioedema has been reported [0m[34m...[0m[34m with laryngeal edema may be fatal.[0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if ENALAPRIL MALEATE increases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler confirmed that ENALAPRIL MALEATE does increase the risk of angioedema, with a higher incidence reported in black patients compared to non-black patients. Angioedema associated with [0m
[32mlaryngeal edema can be fatal, and if it occurs, treatment with ENALAPRIL MALEATE should be discontinued immediately."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"ENALAPRIL MALEATE increases the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ENALAPRIL MALEATE increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if ENALAPRIL MALEATE increases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler confirmed that ENALAPRIL MALEATE does increase the risk of angioedema, with a higher incidence reported in black patients compared to non-black patients. Angioedema associated with [0m
[34mlaryngeal edema can be fatal, and if it occurs, treatment with ENALAPRIL MALEATE should be discontinued immediately."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"ENALAPRIL MALEATE increases the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ENALAPRIL MALEATE increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if ENALAPRIL MALEATE increases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler confirmed that ENALAPRIL MALEATE does increase the risk of angioedema, with a higher incidence reported in black patients compared to non-black patients. Angioedema associated with [0m
[31mlaryngeal edema can be fatal, and if it occurs, treatment with ENALAPRIL MALEATE should be discontinued immediately.[0m
[31m        -----[0m
[31m        Final answer: ENALAPRIL MALEATE increases the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-ENALAPRIL MALEATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe final answer to the question [0m[32m"Does ENALAPRIL MALEATE increase or decrease the risk of angioedema?"[0m[32m is that ENALAPRIL MALEATE increases the risk of angioedema. This information is based on the [0m
[32mresponse from FDAHandler, which referenced the ENALAPRIL MALEATE label indicating that angioedema has been reported in patients receiving the drug. The incidence is higher in black patients compared [0m
[32mto non-black patients, and angioedema associated with laryngeal edema can be fatal. If angioedema occurs, treatment with ENALAPRIL MALEATE should be discontinued and appropriate therapy instituted [0m
[32mimmediately.[0m
